Grifols SA - ADR opened higher at $8.10, compared with its previous close of $8.04. In the last trading session, the stock traded between $8.10 and $8.25. It showed an upward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Grifols SA - ADR is now worth
$ 62.20
resulting in a loss of
$ 37.80 (37.80%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
0%
Hold
100%
Sell
0%
Markets Today
Today's Change
+$0.12 (+1.43%)
Day High
$8.25
Day Low
$8.10
Day Open
$8.10
Prev Close
$8.04
Volume
5,72,453
1W Return
9.39%
1M Return
11.79%
3M Return
0.31%
6M Return
3.10%
1Y Return
-13.15%
Fundamentals
Market Cap ($ Mn)
2,132
PE Ratio
9.99
PB Ratio
0.83
PEG Ratio
0.34
ROE
9.30%
ROCE
6.39%
EPS (TTM)
$0.23
Investment Returns
1 Week
9.39%
1 Month
11.79%
3 Months
0.31%
6 Months
3.10%
9 Months
-12.22%
Financials
Quarterly
All values in $ Mn
1.8K
Mar 25
1.9K
Jun 25
1.9K
Sep 25
2.0K
Dec 25
1.7K
Mar 26
1.9K
Jun 26
Updates
16Jul
Grifols doses first patients in Phase 3 trials to expand Ig indications
Grifols has initiated two Phase 3 trials, SIGMA and XPERT, to expand U.S. indications for GAMUNEX-C and XEMBIFY. SIGMA targets secondary immunodeficiency in blood cancer patients, while XPERT evaluates XEMBIFY for CIDP. These studies aim to offer more treatment options for immune system disorders.
3mo ago
15Jun
Grifols launches FESILTY for congenital fibrinogen deficiency in the U.S.
Grifols has launched FESILTY (fibrinogen, human-chmt) in the U.S. for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency. The FDA-approved product offers rapid reconstitution and predictable dosing, expanding Grifols' plasma-derived medicine portfolio.
